Larazotide
Also known as: Larazotide acetate, AT-1001, INN-202, GGVLVQPG
Synthetic eight-amino-acid peptide that acts as a zonulin antagonist and tight-junction regulator, helping restore and maintain intestinal epithelial barrier function (reducing paracellular 'leaky gut' permeability). It was developed (as larazotide acetate, AT-1001 / INN-202) primarily for celiac disease as an adjunct to a gluten-free diet. It is not FDA-approved: a Phase 3 trial (CeDLara) in celiac disease was discontinued for futility, and the compound remains investigational with no approved human indication. The acetate salt form carries CAS 881851-50-9.
Common research uses
Pricing for Larazotide
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$2.57/mg
range $2.57–$2.57/mg
Sellers
1
from $76.99
45-day trend
0%
vs 45-day avg $/mg
1 of 1 sellers have a current price
- 🇺🇸 Kimera ChemsUnscored
via Disclosed Labs · just now
$2.57/mg 0% vs avg$76.99
30mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for Larazotide
2 third-party tests. Each card links to the full report.
20 citations indexed for Larazotide
review · 2026
Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration
Coeliac disease is characterised by immune-mediated damage to the small intestine in response to dietary gluten in genetically predisposed individuals. Increased intestinal permeability is a central component to its pathophysiology.
animal · 2026
Potassium-Competitive Acid Blocker Increases Ileal Permeability and Exacerbates Ileal Inflammation under Stress Conditions in a Mouse Model of Eosinophilic Enteritis
Introduction Potassium-competitive acid blockers (P-CABs) have been empirically administered to treat non-esophageal eosinophilic gastrointestinal diseases, although their efficacy remains unproven.
review · 2026
Beyond gluten-free diet: Novel therapeutic frontiers in celiac disease armamentarium
Celiac disease is a chronic, immune-mediated enteropathy triggered by dietary gluten ingestion in a genetically susceptible individual.
review · 2026
Integrated Role of Microbial, Fungal, and Plant-Derived Interventions in the Management of Celiac Disease: A Narrative Review
Celiac disease (CeD) is a chronic autoimmune enteropathy triggered by gluten ingestion in genetically susceptible individuals carrying human leukocyte antigen (HLA)-DQ2 or HLA-DQ8 haplotypes.
animal · 2026
Preventive effects of Larazotide acetate (AT-1001) on non-alcoholic fatty liver diseases (NAFLD) in a mouse model
review · 2026
Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance
Celiac disease (CeD) is a chronic autoimmune enteropathy triggered by dietary gluten in genetically predisposed individuals. Currently, a gluten-free diet (GFD) is the only available treatment, being effective in improving mucosal health and symptoms.
Research use only — not for human consumption and not approved by the FDA. Nothing here is medical advice.